INOVIQ (IIQ)

Executive Summary

INOVIQ Ltd (ASX:IIQ) is an Australian biotechnology company focused on next-generation cancer diagnostics and exosome-based therapeutics. The company leverages its proprietary technologies, including SubB2M™, NETs, BARD1, and hTERT, to develop a portfolio of diagnostic assays and capture platforms. INOVIQ's lead commercial product is the hTERT immunocytochemistry assay for bladder cancer detection, which is already generating revenue. Additionally, the EXO-NET® pan-exosome capture platform enables enrichment of exosomes from biological fluids, providing a versatile tool for liquid biopsy and therapeutic applications. The company is actively advancing diagnostic pipelines for ovarian, breast, and other solid tumors, positioning itself as a comprehensive player in the oncology diagnostics space. With a strong intellectual property portfolio and a commercial-stage product, INOVIQ is well-positioned to capture market share in the growing liquid biopsy and cancer diagnostics markets. The company's ability to execute on clinical validation and commercial partnerships will be key to unlocking value. Near-term catalysts include the expansion of its hTERT assay into new geographies, potential partnerships for its EXO-NET platform, and progress in its ovarian cancer diagnostic program. Investors should monitor regulatory developments and clinical data readouts that could drive adoption and revenue growth. Despite the early commercial stage, INOVIQ's diversified pipeline and innovative technologies support a favorable risk-reward profile.

Upcoming Catalysts (preview)

• Q2 2026Expansion of hTERT assay into new markets (e.g., US or Europe)60% success
• Q3 2026Partnership or licensing deal for EXO-NET platform with pharma or diagnostics company40% success
• Q4 2026Clinical data update from ovarian cancer diagnostic trial using SubB2M or BARD150% success